Effects of rokitamycin and other macrolide antibiotics on Mycoplasma pneumoniae in L cells.
Fifty strains of Mycoplasma pneumoniae in L cells were tested for susceptibility to macrolide antibiotics. Rokitamycin, a new macrolide antibiotic, was most active against these organisms, with an MIC for 90% of strains of 0.007 microgram/ml. The MICs of erythromycin, josamycin, and kitasamycin for 90% of strains were 0.03, 0.03, and greater than or equal to 0.06 microgram/ml, respectively. Based on these results, rokitamycin is a promising antibiotic for the treatment of mycoplasmal infections, and further clinical investigations are needed.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004917:Erythromycin / Q000494:pharmacology; D007739:L Cells; D007933:Leucomycins / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D015644:Miocamycin / Q000031:analogs & derivatives*; D009177:Mycoplasma pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D007933:Leucomycins; D015644:Miocamycin; D004917:Erythromycin; C033383:rokitamycin